"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Descriptor ID |
D020522
|
| MeSH Number(s) |
C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525
|
| Concept/Terms |
Lymphoma, Mantle-Cell- Lymphoma, Mantle-Cell
- Lymphoma, Mantle Cell
- Lymphomas, Mantle-Cell
- Mantle-Cell Lymphomas
- Lymphocytic Lymphoma, Diffuse, Poorly Differentiated
- Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated
- Mantle-Zone Lymphoma
- Lymphoma, Mantle-Zone
- Lymphomas, Mantle-Zone
- Mantle Zone Lymphoma
- Mantle-Zone Lymphomas
- Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated
- Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated
- Lymphoma, Small-Cell, Centrocytic
- Mantle-Cell Lymphoma
- Mantle Cell Lymphoma
- Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
- Diffuse Lymphocytic Lymphoma, Poorly Differentiated
- Lymphoma, Centrocytic Small-Cell
- Centrocytic Small-Cell Lymphoma
- Centrocytic Small-Cell Lymphomas
- Lymphoma, Centrocytic Small Cell
- Lymphomas, Centrocytic Small-Cell
- Small-Cell Lymphoma, Centrocytic
- Small-Cell Lymphomas, Centrocytic
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".
This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in this website by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 5 | 1 | 6 |
| 2001 | 4 | 1 | 5 |
| 2002 | 8 | 3 | 11 |
| 2003 | 11 | 1 | 12 |
| 2004 | 2 | 0 | 2 |
| 2005 | 9 | 0 | 9 |
| 2006 | 7 | 2 | 9 |
| 2007 | 5 | 0 | 5 |
| 2008 | 8 | 0 | 8 |
| 2009 | 12 | 2 | 14 |
| 2010 | 12 | 1 | 13 |
| 2011 | 6 | 1 | 7 |
| 2012 | 15 | 0 | 15 |
| 2013 | 18 | 2 | 20 |
| 2014 | 11 | 2 | 13 |
| 2015 | 8 | 0 | 8 |
| 2016 | 9 | 0 | 9 |
| 2017 | 15 | 1 | 16 |
| 2018 | 16 | 1 | 17 |
| 2019 | 12 | 1 | 13 |
| 2020 | 8 | 0 | 8 |
| 2021 | 12 | 0 | 12 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles.
-
Targeting Fc?RIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 04 11; 15(1):42.
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
-
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212.
-
Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. Hum Pathol. 2022 01; 119:59-68.
-
Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Hum Pathol. 2021 12; 118:60-68.
-
Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma. J Cell Mol Med. 2021 11; 25(21):10164-10174.
-
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol. 2021 12; 34(12):2183-2191.
-
The pathologic diagnosis of mantle cell lymphoma. Histol Histopathol. 2021 Oct; 36(10):1037-1051.
-
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021 09 01; 27(17):4690-4695.
-
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021 05 17; 12(1):2877.